BRISBANE, Calif., Feb. 17 /PRNewswire-FirstCall/ -- WHAT: VaxGen, Inc. Senior Vice President, Manufacturing & Operations, Jim Panek, and Vice President, Corporate Affairs,Lance Ignon will co-present a company update at the Roth Capital Partners 18th Annual Growth Conference in Orange County, CA. WHEN/ WHERE: 9:00 a.m. PT, Wednesday, February 22, 2006 St. Regis Resort, Monarch Beach, Dana Point, CA HOW: To listen to a live webcast of the presentation, go to Webcasts in the Investor Relations section of VaxGen's web site at www.vaxgen.com and click on the presentation link for Roth Capital Partners. About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax, smallpox and Meningitis B. The company has been awarded an $877.5 million U.S. government contract to provide 75 million doses of its recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and owns 21% of Celltrion, Inc., a South Korean operation established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company's web site at: http://www.vaxgen.com .
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comVaxGen, Inc.CONTACT: Pat Beaupre Becker of VaxGen, +1-650-624-1041
Web site: http://www.vaxgen.com/
